Extended-Spectrum Beta-Lactamase Production and Carbapenem Resistance in Elderly Urinary Tract Infection Patients: A Multicenter Retrospective Study from Turkey
Abstract
1. Introduction
2. Results
3. Discussions
4. Materials and Methods
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Cortes-Penfield, N.W.; Trautner, B.W.; Jump, R. Urinary tract infection and asymptomatic bacteriuria in older adults. Infect. Dis. Clin. N. Am. 2017, 31, 673. [Google Scholar] [CrossRef] [PubMed]
- Rodriguez-Mañas, L. Urinary tract infections in the elderly: A review of disease characteristics and current treatment options. Drugs Context 2020, 9, 2020-4-13. [Google Scholar] [CrossRef] [PubMed]
- Teillant, A.; Gandra, S.; Barter, D.; Morgan, D.J.; Laxminarayan, R. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: A literature review and modelling study. Lancet Infect. Dis. 2015, 15, 1429–1437. [Google Scholar] [CrossRef] [PubMed]
- Tenney, J.; Hudson, N.; Alnifaidy, H.; Li, J.T.C.; Fung, K.H. Risk factors for aquiring multidrug-resistant organisms in urinary tract infections: A systematic literature review. Saudi Pharm. J. 2018, 26, 678–684. [Google Scholar] [CrossRef] [PubMed]
- Flores-Mireles, A.L.; Walker, J.N.; Caparon, M.; Hultgren, S.J. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 2015, 13, 269–284. [Google Scholar] [CrossRef] [PubMed]
- Hooton, T.M. Uncomplicated urinary tract infection. N. Engl. J. Med. 2012, 366, 1028–1037. [Google Scholar] [CrossRef] [PubMed]
- Girard, R.; Gaujard, S.; Pergay, V.; Pornon, P.; Martin-Gaujard, G.; Bourguignon, L.; Group, U. Risk factors for urinary tract infections in geriatric hospitals. J. Hosp. Infect. 2017, 97, 74–78. [Google Scholar] [CrossRef] [PubMed]
- Aronin, S.I.; Dunne, M.W.; Kalvin, C.Y.; Watts, J.A.; Gupta, V. Increased rates of extended-spectrum beta-lactamase isolates in patients hospitalized with culture-positive urinary Enterobacterales in the United States: 2011–2020. Diagn. Microbiol. Infect. Dis. 2022, 103, 115717. [Google Scholar] [CrossRef] [PubMed]
- Mouanga Ndzime, Y.; Onanga, R.; Kassa Kassa, R.F.; Bignoumba, M.; Mbehang Nguema, P.P.; Gafou, A.; Lendamba, R.W.; Mbombe Moghoa, K.; Bisseye, C. Epidemiology of community origin Escherichia coli and Klebsiella pneumoniae uropathogenic strains resistant to antibiotics in Franceville, Gabon. Infect. Drug Resist. 2021, 14, 585–594. [Google Scholar] [CrossRef] [PubMed]
- NADİR, Y.; BATIREL, A.A. Review of Colistin Susceptibility Testing with Current Data. Mediterr. J. Infect. Microbes Antimicrob. 2024, 13, 24056.3. [Google Scholar]
- Suemer, S.; Ayguen, G.; AKALIN, E.; Akova, M.; KÖKSAL, I. Common problems and solutions in the management of resistant Gram-negative bacterial infections: Expert opinion on clinical practice. Flora Infeksiyon Hastalik. VE Klin. Mikrobiyoloji Derg. 2024, 29, 1–24. [Google Scholar]
- Jalil, M.B.; Al Atbee, M.Y.N. The prevalence of multiple drug resistance Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infections. J. Clin. Lab. Anal. 2022, 36, e24619. [Google Scholar] [CrossRef] [PubMed]
- Yang, X.; Chen, H.; Zheng, Y.; Qu, S.; Wang, H.; Yi, F. Disease burden and long-term trends of urinary tract infections: A worldwide report. Front. Public Health 2022, 10, 888205. [Google Scholar] [CrossRef] [PubMed]
- Abrams, P.; Andersson, K.-E.; Birder, L.; Brubaker, L.; Cardozo, L.; Chapple, C.; Cottenden, A.; Davila, W.; De Ridder, D.; Dmochowski, R. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol. Urodyn. 2010, 29, 213–240. [Google Scholar] [CrossRef] [PubMed]
- Wagenlehner, F.M.; Bjerklund Johansen, T.E.; Cai, T.; Koves, B.; Kranz, J.; Pilatz, A.; Tandogdu, Z. Epidemiology, definition and treatment of complicated urinary tract infections. Nat. Rev. Urol. 2020, 17, 586–600. [Google Scholar] [CrossRef] [PubMed]
- Wojszel, Z.B.; Toczyńska-Silkiewicz, M. Urinary tract infections in a geriatric sub-acute ward-health correlates and atypical presentations. Eur. Geriatr. Med. 2018, 9, 659–667. [Google Scholar] [CrossRef] [PubMed]
- Girma, A.; Aemiro, A. The bacterial profile and antimicrobial susceptibility patterns of urinary tract infection patients at Pawe General Hospital, Northwest Ethiopia. Scientifica 2022, 2022, 3085950. [Google Scholar] [CrossRef] [PubMed]
- Mayne, S.; Bowden, A.; Sundvall, P.-D.; Gunnarsson, R. The scientific evidence for a potential link between confusion and urinary tract infection in the elderly is still confusing-a systematic literature review. BMC Geriatr. 2019, 19, 1–15. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance, to Guide Research, Development, and Strategies to Prevent and Control Antimicrobial Resistance; World Health Organization: Geneva, Switzerland, 2024. [Google Scholar]
- Reta, A.; Bitew Kifilie, A.; Mengist, A. Bacterial infections and their antibiotic resistance pattern in ethiopia: A systematic review. Adv. Prev. Med. 2019, 2019, 4380309. [Google Scholar] [CrossRef] [PubMed]
- Cohen Stuart, J.; Leverstein-Van Hall, M.; Kortmann, W.; Verlind, J.; Mulder, F.; Scharringa, J.; Fluit, A.; Ekkelenkamp, M. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: A retrospective observational case-series. Eur. J. Clin. Microbiol. Infect. Dis. 2018, 37, 2021–2025. [Google Scholar] [CrossRef] [PubMed]
- van Driel, A.A.; Notermans, D.; Meima, A.; Mulder, M.; Donker, G.; Stobberingh, E.; Verbon, A. Antibiotic resistance of Escherichia coli isolated from uncomplicated UTI in general practice patients over a 10-year period. Eur. J. Clin. Microbiol. Infect. Dis. 2019, 38, 2151–2158. [Google Scholar] [CrossRef] [PubMed]
- Naziri, Z.; Derakhshandeh, A.; Soltani Borchaloee, A.; Poormaleknia, M.; Azimzadeh, N. Treatment failure in urinary tract infections: A warning witness for virulent multi-drug resistant ESBL-producing Escherichia coli. Infect. Drug Resist. 2020, 13, 1839–1850. [Google Scholar] [CrossRef] [PubMed]
- Taha, R.; Kader, O.; Shawky, S.; Rezk, S. Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: A glimmer of hope. Ann. Clin. Microbiol. Antimicrob. 2023, 22, 21. [Google Scholar] [CrossRef] [PubMed]
- Fésüs, A.; Matuz, M.; Papfalvi, E.; Hambalek, H.; Ruzsa, R.; Tánczos, B.; Bácskay, I.; Lekli, I.; Illés, Á.; Benkő, R. Evaluation of the diagnosis and antibiotic prescription pattern in patients hospitalized with urinary tract infections: Single-center study from a university-affiliated hospital. Antibiotics 2023, 12, 1689. [Google Scholar] [CrossRef] [PubMed]
- Maraki, S.; Mavromanolaki, V.E.; Stafylaki, D.; Iliaki-Giannakoudaki, E.; Kasimati, A. Antimicrobial resistance trends among Klebsiella pneumoniae associated with urinary tract infections in Crete, Greece, 2017–2022. Acta Microbiol. Et Immunol. Hung. 2024, 71, 121–126. [Google Scholar] [CrossRef] [PubMed]
- Armstrong, N. Overdiagnosis and overtreatment as a quality problem: Insights from healthcare improvement research. BMJ Qual. Saf. 2018, 27, 571–575. [Google Scholar] [CrossRef] [PubMed]
- Rousham, E.; Cooper, M.; Petherick, E.; Saukko, P.; Oppenheim, B. Overprescribing antibiotics for asymptomatic bacteriuria in older adults: A case series review of admissions in two UK hospitals. Antimicrob. Resist. Infect. Control 2019, 8, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Abraham, K. Genotypic Susceptibility, Phylotyping and CH Clonotyping of Porcine E. coli Isolates. 2022. Available online: https://services.phaidra.vetmeduni.ac.at/api/object/o:2595/download (accessed on 15 May 2025).
- Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022, 399, 629–655. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.; Qiu, S.; Chen, M.; Lyu, J.; Yu, G.; Xue, L. A clinical prediction tool for extended-spectrum β-lactamase-producing Enterobacteriaceae urinary tract infection. BMC Infect. Dis. 2022, 22, 50. [Google Scholar] [CrossRef] [PubMed]
- García-Vázquez, E.; Canteras, M.; Hernandez-Torres, A. Predictive factors of ESBL versus non-ESBL Escherichia coli bacteraemia and influence of resistance on the mortality of the patients. Med. Clin. 2010, 136, 56–60. [Google Scholar]
- Larramendy, S.; Deglaire, V.; Dusollier, P.; Fournier, J.-P.; Caillon, J.; Beaudeau, F.; Moret, L. Risk factors of extended-spectrum beta-lactamases-producing Escherichia coli community acquired urinary tract infections: A systematic review. Infect. Drug Resist. 2020, 13, 3945–3955. [Google Scholar] [CrossRef] [PubMed]
- Moghnieh, R.; Abdallah, D.; Jadayel, M.; Zorkot, W.; El Masri, H.; Dib, M.J.; Omar, T.; Sinno, L.; Lakkis, R.; Jisr, T. Epidemiology, risk factors, and prediction score of carbapenem resistance among inpatients colonized or infected with 3rd generation cephalosporin resistant Enterobacterales. Sci. Rep. 2021, 11, 14757. [Google Scholar] [CrossRef] [PubMed]
- Yao, H.; Yang, Y.; Yao, H.; Bu, S.; Li, L.; Wang, F.; Zhang, J.; Chen, J. Development of prediction models for carbapenem-resistant Klebsiella pneumoniae acquisition and prognosis in adult patients. Front. Pharmacol. 2024, 15, 1439116. [Google Scholar] [CrossRef] [PubMed]
- Cetin, S.; Dokmetas, I.; Hamidi, A.A.; Bayraktar, B.; Gunduz, A.; Sevgi, D.Y. Comparison of risk factors and outcomes in carbapenem-resistant and carbapenem-susceptible Gram-negative bacteremia. Med. Bull. Sisli Etfal Hosp. 2021, 55, 398. [Google Scholar] [CrossRef] [PubMed]
Parameter | N (%) |
---|---|
Gender Female Male | 353 (45.5) 423 (54.5) |
Place of Admission Ward Intensive Care Unit | 656 (84.5) 120 (15.5) |
Dysuria Present Absent | 299 (38.5) 477 (61.5) |
Hematuria Present Absent | 52 (6.7) 724 (93.3) |
Flank Pain Present Absent | 82 (10.6) 694 (89.4) |
Groin Pain Present Absent | 125 (16.1) 651 (83.9) |
Urinary Incontinence Present Absent | 290 (37.4) 486 (62.6) |
Nausea Present Absent | 159 (20.5) 617 (79.5) |
Vomiting Present Absent | 115 (14.8) 661 (85.2) |
Fever Present Absent | 342 (44.1) 434 (55.9) |
Confusion Present Absent | 198 (25.5) 578 (74.5) |
Poor Oral Intake Present Absent | 324 (41.8) 452 (58.2) |
Comorbidities | N (%) |
---|---|
Hypertension Present Absent | 557 (71.8) 219 (28.2) |
Diabetes Mellitus Present Absent | 318 (41) 458 (59) |
Chronic Obstructive Pulmonary Disease Present Absent | 188 (24.2) 588 (75.8) |
Coronary Artery Disease Present Absent | 424 (54.6) 352 (45.4) |
Dementia Present Absent | 339 (43.7) 437 (56.3) |
Cerebrovascular Disease Present Absent | 159 (20.5) 617 (79.5) |
Congestive Heart Failure Present Absent | 108 (13.9) 668 (86.1) |
Chronic Kidney Disease Present Absent | 277 (35.7) 499 (64.3) |
Benign Prostatic Hyperplasia Present Absent | 251 (32.3) 525 (67.7) |
Renal Transplant Present Absent | 3 (0.4) 773 (99.6) |
Kidney Stone Present Absent | 73 (9.4) 703 (90.6) |
Urogenital Malignancy Present Absent | 106 (13.7) 670 (86.3) |
Urinary Foreign Body Chronic Catheter Use Present Absent Nephrostomy Present Absent Double-J Stent Present Absent | 98 (12.6) 678 (87.4) 41(5.3) 735 (94.7) 30 (3.9) 746 (3.9) |
Carbapenem | Extended-Spectrum Beta-Lactamase | Son Durum | ||||
---|---|---|---|---|---|---|
Sensitive n (%) | Resistance n (%) | Nonproducer n (%) | Producer n (%) | Alive n (%) | Dead n (%) | |
Escherichia coli | 332 (98.8) | 4 (1.2) | 111 (43.2) | 146 (56.8) | 313 (86.9) | 47 (13.1) |
Klebsiella | 74 (62.2) | 45 (37.8) | 30 (34.9) | 56 (65.1) | 110 (89.4) | 13 (10.6) |
Pseudomonas | 26 (83.9) | 5 (16.1) | 2 (20) | 8 (80) | 30 (90.9) | 3 (9.1) |
Other | 18 (94.7) | 1 (5.3) | 8 (57.1) | 6 (42.9) | 19 (86.4) | 3 (13.6) |
Proteus | 11 (91.7) | 1 (8.3) | 3 (42.9) | 4 (57.1) | 10 (76.9) | 3 (23.1) |
Acinetobacter | 2 (50) | 2 (50) | 0 | 2 (100) | 4 (80) | 1 (20) |
ESBL Production Pearson Chi-Square Analysis | Binary Logistic Regression Analysis | |||||
---|---|---|---|---|---|---|
No | Yes | p Score | Odds Ratio | Confidence Interval | p Score | |
Gender Female Male | 83 (48.0) 71 (34.5) | 90 (52.0) 135 (65.5) | 0.008 | Ref. 1.44 | 0.90–2.29 | 0.124 |
Age 65–74.9 75–84.9 ≥85 | 57 (35.8) 59 (42.4) 38 (40.6) | 102 (64.2) 80 (57.6) 43 (59.4) | 0.221 | |||
Place of Admission Ward Intensive Care Unit | 132 (40.6) 22 (40.7) | 193 (59.4) 32 (59.3) | 0.986 | |||
Diabetes Mellitus Absent Present | 82 (37.4) 72 (45.0) | 137 (62.6) 88 (55.0) | 0.139 | |||
Benign Prostatic Hyperplasia Absent Present | 117 (39.9) 37 (43.0) | 176 (60.1) 49 (57.0) | 0.608 | |||
Kidney Stone Absent Present | 142 (41.5) 12 (32.4) | 200 (58.5) 25 (67.6) | 0.285 | |||
Urogenital Malignancy Absent Present | 137 (43.6) 17 (26.2) | 177 (56.4) 48 (73.8) | 0.009 | Ref. 2.30 | 1.17–4.51 | 0.016 |
Urinary Foreign Body Absent Present | 125 (43.9) 29 (30.9) | 160 (56.1) 65 (69.1) | 0.026 | Ref. 1.08 | 0.60–1.94 | 0.788 |
Hospitalization Within 6 Months Absent Present | 98 (52.7) 56 (29.0) | 88 (47.3) 137 (71.0) | <0.001 | Ref. 1.40 | 0.81–2.40 | 0.219 |
Antibiotic Use Within 3 Months Absent Present | 75 (60.5) 79 (31.0) | 49 (39.5) 176 (69.0) | <0.001 | Ref. 3.16 | 1.99–5.02 | <0.001 |
Agent Escherichia coli Klebsiella Pseudomonas Proteus Acinetobacter | 111 (43.2) 30 (34.9) 2 (20.0) 3 (42.9) 0 (0) | 146 (56.8) 56 (65.1) 8 (80.0) 4 (57.1) 2 (100.0) | <0.001 | Ref. 0.97 2.73 0.69 - | 0.56–1.70 0.51–14.52 0.13–3.60 - | 0.803 0.938 0.239 0.669 0.999 |
Carbapenem Resistance Pearson Chi-Square Analysis | Binary Logistic Regression Analysis | |||||
---|---|---|---|---|---|---|
No | Yes | p Score | Odds Ratio | Confidence Interval | p Score | |
Gender Female Male | 225 (90.7) 244 (87.1) | 23 (9.3) 36 (12.9) | 0.192 | |||
Age 65–74.9 75–84.9 ≥85 | 168 (89.4) 187 (90.3) 114 (85.7) | 20 (10.6) 20 (9.7) 19 (14.3) | 0.401 | |||
Place of Admission Ward Intensive Care Unit | 388 (88.4) 81 (91.0) | 51 (11.6) 8 (9.0) | 0.473 | |||
Diabetes Mellitus Absent Present | 274 (87.8) 195 (12.2) | 38 (90.3) 21 (9.7) | 0.378 | |||
Benign Prostatic Hyperplasia Absent Present | 337 (88.5) 132 (89.8) | 44 (11.5) 15 (10.2) | 0.660 | |||
Kidney Stone Absent Present | 421 (41.5) 48 (32.4) | 58 (58.5) 1 (67.6) | 0.031 | Ref. 0.082 | 0.01–0.65 | 0.018 |
Urogenital Malignancy Absent Present | 408 (90.7) 61 (78.2) | 42 (9.3) 17 (21.8) | 0.001 | Ref. 0.75 | 0.33–1.66 | 0.484 |
Urinary Foreign Body Absent Present | 375 (91.5) 94 (79.7) | 35 (8.5) 24 (20.3) | <0.001 | Ref. 1.16 | 0.53–2.55 | 0.701 |
Hospitalization Within 6 Months Absent Present | 243 (98.0) 226 (80.7) | 5 (2.0) 54 (19.3) | <0.001 | Ref. 8.55 | 3.14–23.24 | <0.001 |
Antibiotic Use Within 3 Months Absent Present | 158 (96.9) 311 (85.2) | 5 (3.1) 54 (14.8) | <0.001 | Ref. 1.44 | 0.40–5.18 | 0.571 |
Agent Escherichia coli Klebsiella Pseudomonas Proteus Acinetobacter | 332 (98.8) 74 (62.2) 26 (83.9) 11 (91.7) 2 (50.0) | 4 (1.2) 45 (37.8) 5 (16.1) 1 (8.3) 2 (50.0) | <0.001 | 1 44.76 18.13 4.68 61.99 | 15.28–131.07 4.34–75.75 0.47–3.46.64 5.89–652.32 | <0.001 <0.001 <0.001 0.188 0.001 |
Odds Ratio | Confidence Interval | p Score | |
---|---|---|---|
Place of Admission Intensive Care Unit vs. ward | 4.35 | 2.44–7.75 | <0.001 |
Agent Gram-Positive vs. Negative | 4.09 | 1.83–9.14 | 0.001 |
COPD Present vs. Absent | 2.32 | 1.31–4.10 | 0.004 |
Urinary Incontinence Present vs. Absent | 1.88 | 1.09–3.24 | 0.022 |
Altered Mental Status Present vs. Absent | 3.39 | 1.93–5.96 | <0.001 |
Poor Oral Intake Present vs. Absent | 1.56 | 0.91–2.69 | 0.104 |
Coronary Artery Disease Present vs. Absent | 1.23 | 0.70–2.16 | 0.470 |
Chronic Heart Failure Present vs. Absent | 1.05 | 0.52–2.10 | 0.882 |
Dementia Present vs. Absent | 0.85 | 0.44–1.64 | 0.640 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yıldırım, Ç.; Sarı, S.; Parmaksızoğlu Aydın, A.M.; Kilinç Toker, A.; Turunç Özdemir, A.; Erdem Kıvrak, E.; Mermer, S.; Kahraman, H.; Soysal, O.; Yıldırım, H.Ç.; et al. Extended-Spectrum Beta-Lactamase Production and Carbapenem Resistance in Elderly Urinary Tract Infection Patients: A Multicenter Retrospective Study from Turkey. Antibiotics 2025, 14, 719. https://doi.org/10.3390/antibiotics14070719
Yıldırım Ç, Sarı S, Parmaksızoğlu Aydın AM, Kilinç Toker A, Turunç Özdemir A, Erdem Kıvrak E, Mermer S, Kahraman H, Soysal O, Yıldırım HÇ, et al. Extended-Spectrum Beta-Lactamase Production and Carbapenem Resistance in Elderly Urinary Tract Infection Patients: A Multicenter Retrospective Study from Turkey. Antibiotics. 2025; 14(7):719. https://doi.org/10.3390/antibiotics14070719
Chicago/Turabian StyleYıldırım, Çiğdem, Sema Sarı, Ayşe Merve Parmaksızoğlu Aydın, Aysin Kilinç Toker, Ayşe Turunç Özdemir, Esra Erdem Kıvrak, Sinan Mermer, Hasip Kahraman, Orçun Soysal, Hasan Çağrı Yıldırım, and et al. 2025. "Extended-Spectrum Beta-Lactamase Production and Carbapenem Resistance in Elderly Urinary Tract Infection Patients: A Multicenter Retrospective Study from Turkey" Antibiotics 14, no. 7: 719. https://doi.org/10.3390/antibiotics14070719
APA StyleYıldırım, Ç., Sarı, S., Parmaksızoğlu Aydın, A. M., Kilinç Toker, A., Turunç Özdemir, A., Erdem Kıvrak, E., Mermer, S., Kahraman, H., Soysal, O., Yıldırım, H. Ç., & Tasbakan, M. I. (2025). Extended-Spectrum Beta-Lactamase Production and Carbapenem Resistance in Elderly Urinary Tract Infection Patients: A Multicenter Retrospective Study from Turkey. Antibiotics, 14(7), 719. https://doi.org/10.3390/antibiotics14070719